{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:11:46Z","timestamp":1792289506458,"version":"4.4.0"},"reference-count":25,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2017,10,10]],"date-time":"2017-10-10T00:00:00Z","timestamp":1507593600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2017,10,10]],"date-time":"2017-10-10T00:00:00Z","timestamp":1507593600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Clin Pract"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1111\/ijcp.13032","type":"journal-article","created":{"date-parts":[[2017,10,10]],"date-time":"2017-10-10T10:16:36Z","timestamp":1507630596000},"page":"e13032","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Pro-protein subtilisin kexin-9 (PCSK9) inhibition in practice: lipid clinic experience in 2 contrasting UK centres"],"prefix":"10.1155","volume":"71","author":[{"given":"Monika","family":"Kohli","sequence":"first","affiliation":[{"name":"Department of Metabolic Medicine\/Chemical Pathology; Guy's & St Thomas\u2019 Hospitals; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinjal","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine\/Chemical Pathology; Queen's Hospital; Burton-on-Trent UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zofia","family":"MacMahon","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine\/Chemical Pathology; Guy's & St Thomas\u2019 Hospitals; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radha","family":"Ramachandran","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine\/Chemical Pathology; Guy's & St Thomas\u2019 Hospitals; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin A.","family":"Crook","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine\/Chemical Pathology; Guy's & St Thomas\u2019 Hospitals; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9729-4775","authenticated-orcid":false,"given":"Timothy M.","family":"Reynolds","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine\/Chemical Pathology; Queen's Hospital; Burton-on-Trent UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2756-372X","authenticated-orcid":false,"given":"Anthony S.","family":"Wierzbicki","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine\/Chemical Pathology; Guy's & St Thomas\u2019 Hospitals; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,10,10]]},"reference":[{"key":"10.1111\/ijcp.13032-BIB0001|ijcp13032-cit-0001","doi-asserted-by":"crossref","first-page":"353","DOI":"10.7861\/clinmedicine.16-4-353","article-title":"Drugs for hypercholesterolaemia-from statins to pro-protein convertase subtilisin kexin 9 (PCSK9) inhibition","volume":"16","author":"Wierzbicki","year":"2016","journal-title":"Clin Med (Lond)"},{"key":"10.1111\/ijcp.13032-BIB0002|ijcp13032-cit-0002","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/s41598-017-00316-3","article-title":"Therapeutic efficacy and safety of PCSK9-monoclonal antibodies on familial hypercholesterolemia and statin-intolerant patients: a meta-analysis of 15 randomized controlled trials","volume":"7","author":"Qian","year":"2017","journal-title":"Sci Rep"},{"key":"10.1111\/ijcp.13032-BIB0003|ijcp13032-cit-0003","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1093\/eurheartj\/ehv563","article-title":"The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis","volume":"37","author":"Lipinski","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1111\/ijcp.13032-BIB0004|ijcp13032-cit-0004","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","article-title":"Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial","volume":"9","author":"Moriarty","year":"2015","journal-title":"J Clin Lipidol"},{"key":"10.1111\/ijcp.13032-BIB0005|ijcp13032-cit-0005","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","article-title":"Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab","volume":"63","author":"Stroes","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/ijcp.13032-BIB0006|ijcp13032-cit-0006","first-page":"1","volume-title":"Alirocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia (TA393)","author":"National Institute for Health and Clinical Excellence","year":"2016"},{"key":"10.1111\/ijcp.13032-BIB0007|ijcp13032-cit-0007","first-page":"1","volume-title":"Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia","author":"National Institute for Health and Clinical Excellence","year":"2016"},{"key":"10.1111\/ijcp.13032-BIB0008|ijcp13032-cit-0008","first-page":"2245","article-title":"European Society of Cardiology\/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin\/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk","volume":"38","author":"Landmesser","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1111\/ijcp.13032-BIB0009|ijcp13032-cit-0009","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.jacl.2017.05.001","article-title":"Update on the use of PCSK9 inhibitors in adults: recommendations from an expert panel of the National Lipid Association","volume":"11","author":"Orringer","year":"2017","journal-title":"J Clin Lipidol"},{"key":"10.1111\/ijcp.13032-BIB0010|ijcp13032-cit-0010","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.2016.11004","article-title":"Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease","volume":"316","author":"Kazi","year":"2016","journal-title":"JAMA"},{"key":"10.1111\/ijcp.13032-BIB0011|ijcp13032-cit-0011","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s40273-017-0492-6","article-title":"Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia: an evidence review group perspective of a NICE single technology appraisal","volume":"35","author":"Carroll","year":"2017","journal-title":"Pharmacoeconomics"},{"key":"10.1111\/ijcp.13032-BIB0012|ijcp13032-cit-0012","doi-asserted-by":"crossref","first-page":"g4356","DOI":"10.1136\/bmj.g4356","article-title":"Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance","volume":"349","author":"Rabar","year":"2014","journal-title":"BMJ"},{"key":"10.1111\/ijcp.13032-BIB0013|ijcp13032-cit-0013","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation"},{"key":"10.1111\/ijcp.13032-BIB0014|ijcp13032-cit-0014","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","article-title":"2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)","volume":"37","author":"Piepoli","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1111\/ijcp.13032-BIB0015|ijcp13032-cit-0015","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/j.1742-1241.2007.01667.x","article-title":"The value of a specialist lipid clinic","volume":"62","author":"Martin","year":"2008","journal-title":"Int J Clin Pract"},{"key":"10.1111\/ijcp.13032-BIB0016|ijcp13032-cit-0016","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/HCO.0000000000000282","article-title":"Statin myopathy: over-rated and under-treated?","volume":"31","author":"Maghsoodi","year":"2016","journal-title":"Curr Opin Cardiol"},{"key":"10.1111\/ijcp.13032-BIB0017|ijcp13032-cit-0017","unstructured":"National Institute for Health and Clinical Excellence Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia https:\/\/www.nice.org.uk\/guidance\/ta385"},{"key":"10.1111\/ijcp.13032-BIB0018|ijcp13032-cit-0018","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1185\/03007995.2012.657302","article-title":"Daily and intermittent rosuvastatin 5\u00a0mg therapy in statin intolerant patients: an observational study","volume":"28","author":"Meek","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.1111\/ijcp.13032-BIB0019|ijcp13032-cit-0019","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.jacl.2016.09.003","article-title":"Double-heterozygous autosomal dominant hypercholesterolemia: clinical characterization of an underreported disease","volume":"10","author":"Sjouke","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1111\/ijcp.13032-BIB0020|ijcp13032-cit-0020","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1161\/CIRCGENETICS.115.001129","article-title":"Characterization of autosomal dominant hypercholesterolemia caused by PCSK9 gain of function mutations and its specific treatment with alirocumab, a PCSK9 monoclonal antibody","volume":"8","author":"Hopkins","year":"2015","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1111\/ijcp.13032-BIB0021|ijcp13032-cit-0021","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.amjcard.2016.09.010","article-title":"Effect of alirocumab on lipoprotein(a) Over >\/=1.5 Years (from the Phase 3 ODYSSEY program)","volume":"119","author":"Gaudet","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1111\/ijcp.13032-BIB0022|ijcp13032-cit-0022","doi-asserted-by":"crossref","first-page":"24392","DOI":"10.1038\/srep24392","article-title":"Pioglitazone enhances the beneficial effects of glucocorticoids in experimental nephrotic syndrome","volume":"6","author":"Agrawal","year":"2016","journal-title":"Sci Rep"},{"key":"10.1111\/ijcp.13032-BIB0023|ijcp13032-cit-0023","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12944-016-0197-4","article-title":"Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: analysis of 3 randomized trials versus placebo","volume":"15","author":"Toth","year":"2016","journal-title":"Lipids Health Dis"},{"key":"10.1111\/ijcp.13032-BIB0024|ijcp13032-cit-0024","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12933-017-0552-4","article-title":"Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk","volume":"16","author":"Muller-Wieland","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"10.1111\/ijcp.13032-BIB0025|ijcp13032-cit-0025","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jacl.2017.02.014","article-title":"Proprotein convertase subtilisin\/kexin 9 inhibition in patients with familial hypercholesterolemia: initial clinical experience","volume":"11","author":"Galema-Boers","year":"2017","journal-title":"J Clin Lipidol"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fijcp.13032","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/ijcp.13032\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T06:10:13Z","timestamp":1643350213000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijcp.13032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,10]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"URL":"https:\/\/doi.org\/10.1111\/ijcp.13032","archive":["Portico"],"relation":{},"ISSN":["1368-5031"],"issn-type":[{"value":"1368-5031","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10,10]]}}}